Anti-ictogenic effects of the corticotropin-releasing factor-like peptide in the pentylenetetrazole model of seizure in brain slices

Highlights • The MTX mini-peptide has shown anticonvulsant activity in the PTZ model of seizure. • MTX has long-term efficacy in inhibiting/suppressing ictal- and interictal-like activities. • MTX's protective effects were concentration- and time-dependent. • An enzymatic treatment of MTX is ac...

Full description

Saved in:
Bibliographic Details
Published inEpilepsy research Vol. 108; no. 3; pp. 587 - 591
Main Author Mokrushin, Anatoly A
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier B.V 01.03.2014
Elsevier
Subjects
Action Potentials - drug effects
AMPA
Animals
Anticonvulsants - pharmacology
Brain slices
Cerebral Cortex - drug effects
Convulsants - pharmacology
Dose-Response Relationship, Drug
Epileptiform discharges
EPSP
In Vitro Techniques
Male
Mystixin
Neurology
NMDA
Oligopeptides - pharmacology
Pentylenetetrazole - pharmacology
Rats
Rats, Wistar
Reaction Time - drug effects
Statistics, Nonparametric
NMDA
EPSP
Brain slices
AMPA
Epileptiform discharges
Mystixin
Online AccessGet full text

Cover

More Information
Summary:Highlights • The MTX mini-peptide has shown anticonvulsant activity in the PTZ model of seizure. • MTX has long-term efficacy in inhibiting/suppressing ictal- and interictal-like activities. • MTX's protective effects were concentration- and time-dependent. • An enzymatic treatment of MTX is accompanied by a decrease in the frequency pattern EDs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0920-1211
1872-6844
DOI:10.1016/j.eplepsyres.2014.01.002